GlaxoSmithKline's HPV Vaccine, Cervarix.
A routine immunisation programme for human papillomavirus (HPV) started across the UK on 1 September 2008 for 12–13-year-old girls (school year 8). The vaccine given is called Cervarix, which protects against infection with HPV types 16 and 18.
Here is my following email to the MHRA.
----- Original Message -----
To: MHRA Information Centre
Sent: Monday, September 15, 2008 12:02 PM
Subject: FOI - Cervarix, (HPV) vaccine
Dear Sir, Madam,
I wish to learn more of GlaxoSmithKline's HPV Vaccine, Cervarix and the MHRA's stance on it.
Could you confirm the following in writing to me please?
1. Is GlaxoSmithKline's, Cervarix, a vaccine to prevent cervical cancer?
2. Can the Human Papilloma Virus [HPV] cause cervical cancer?
3. Can GlaxoSmithKline's HPV vaccine, Cervarix, increase the risk of precancerous lesions?
4. Is GlaxoSmithKline's HPV vaccine, Cervarix, effective amongst women and girls under the age of sexual consent whom have had prior exposure to HPV?
5. Is GlaxoSmithKline's HPV vaccine, Cervarix, only effective in virgins?
6. As I am aware via the MHRA website [HERE] a routine immunisation programme for human papillomavirus (HPV) started across the UK on 1 September 2008. With this in mind, has any criteria been set-up to ask patients [before administering the vaccine] whether or not they have had sexual intercourse?
I ask all of the above under the Freedom of Information Act.
*Interested parties blind copied
Read the new book, The Evidence, However, Is Clear...The Seroxat Scandal
By Bob Fiddaman
AVAILABLE FOR DOWNLOAD HERE
PAPERBACK COMING SOON